CAMBRIDGE, Mass.--(BUSINESS WIRE)--Imara Inc. today announced it will report additional preclinical and Phase 1 clinical data from the company’s lead compound, IMR-687, a once-daily, oral therapy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback